Skip to main content
SpringerLink
Log in
Book cover

Handbook of Diabetes Technology pp 75–82Cite as

Islet Transplantation

  • Chapter
  • First Online:

  • 897 Accesses

Abstract

Type 1 diabetes mellitus is an autoimmune disease leading to an irreversible ß-cell deficit responsible for a complete insulin secretion deficiency. To date, no preventive or curative treatment for type 1 diabetes mellitus has been successfully translated to standard clinical care. Type 1 diabetes treatment is based on lifelong multi-daily injections of exogenous insulin. In the last decades, considerable improvements in diabetes management have occurred: thanks to an intensive disease management and the widespread use of new therapies such as new insulin formulations and new medical devices (insulin pump, real-time continuous glucose monitoring system, improved glucose monitoring system), the overall glycemic control of patients with type 1 diabetes has improved, and the incidence of long-term diabetic complications and the mortality of type 1 diabetic patients have decreased.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Beck RW, et al. The T1D Exchange clinic registry. J Clin Endocrinol Metab. 2012;97(12):4383–9.

    Article  CAS  Google Scholar 

  2. Lind M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371(21):1972–82.

    Article  Google Scholar 

  3. Livingstone SJ, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA. 2015;313(1):37–44.

    Article  CAS  Google Scholar 

  4. Gruessner AC, Gruessner RW. Pancreas transplant outcomes for United States and non United States cases as reported to the United Network for Organ Sharing and the International Pancreas Transplant Registry as of December 2011. Clin Transpl. 2012:23–40.

    Google Scholar 

  5. Benhamou PY, et al. Quality of life after islet transplantation: data from the GRAGIL 1 and 2 trials. Diabet Med. 2009;26(6):617–21.

    Article  CAS  Google Scholar 

  6. Tanenberg RJ, Newton CA, Drake AJ. Confirmation of hypoglycemia in the “dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract. 2010;16(2):244–8.

    Article  Google Scholar 

  7. McCoy RG, et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35(9):1897–901.

    Article  Google Scholar 

  8. Barr CC. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive insulin therapy, by The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342:381–9. Surv Ophthalmol. 2001;45(5):459–60.

    Article  CAS  Google Scholar 

  9. Spijker HS, et al. Islet-after-lung transplantation in a patient with cystic fibrosis-related diabetes. Diabetes Care. 2014;37(7):e159–60.

    Article  Google Scholar 

  10. Ricordi C, et al. Automated method for isolation of human pancreatic islets. Diabetes. 1988;37(4):413–20.

    Article  CAS  Google Scholar 

  11. Yamamoto T, et al. Quality control for clinical islet transplantation: organ procurement and preservation, the islet processing facility, isolation, and potency tests. J Hepatobiliary Pancreat Surg. 2009;16(2):131–6.

    Article  Google Scholar 

  12. Services USDoHaH, Administration FaD, Research CfBEa. Guidance for industry: Considerations for allogeneic pancreatic islet cell products. 2009.

    Google Scholar 

  13. Badet L, et al. Expectations and strategies regarding islet transplantation: metabolic data from the GRAGIL 2 trial. Transplantation. 2007;84(1):89–96.

    Article  CAS  Google Scholar 

  14. Brons G. One more step along the road. Transplantation. 2007;84(1):15–6.

    Article  Google Scholar 

  15. Rickels MR, et al. Defining outcomes for beta-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop. Transpl Int. 2018;31(4):343–52.

    Article  CAS  Google Scholar 

  16. Lehmann R, et al. Has time come for new goals in human islet transplantation? Am J Transplant. 2008;8(6):1096–100.

    Article  CAS  Google Scholar 

  17. Hering BJ, et al. Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia. Diabetes Care. 2016;39(7):1230–40.

    Article  CAS  Google Scholar 

  18. Lablanche S, et al. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(7):527–37.

    Article  CAS  Google Scholar 

  19. Lablanche S, et al. Five-year metabolic, functional, and safety results of patients with type 1 diabetes transplanted with allogenic islets within the Swiss-French GRAGIL Network. Diabetes Care. 2015;38(9):1714–22.

    Article  CAS  Google Scholar 

  20. Shapiro AM, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343(4):230–8.

    Article  CAS  Google Scholar 

  21. Linetsky E, et al. Improved human islet isolation using a new enzyme blend, liberase. Diabetes. 1997;46(7):1120–3.

    Article  CAS  Google Scholar 

  22. Barton FB, et al. Improvement in outcomes of clinical islet transplantation: 1999–2010. Diabetes Care. 2012;35(7):1436–45.

    Article  CAS  Google Scholar 

  23. Bellin MD, et al. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplant. 2008;8(11):2463–70.

    Article  CAS  Google Scholar 

  24. Bellin MD, et al. Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant. 2012;12(6):1576–83.

    Article  CAS  Google Scholar 

  25. Biarnes M, et al. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes. 2002;51(1):66–72.

    Article  CAS  Google Scholar 

  26. Fiorina P, et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care. 2005;28(6):1358–65.

    Article  Google Scholar 

  27. Bassi R, Fiorina P. Impact of islet transplantation on diabetes complications and quality of life. Curr Diab Rep. 2011;11(5):355–63.

    Article  Google Scholar 

  28. Fiorina P, et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol. 2003;14(8):2150–8.

    Article  Google Scholar 

  29. Andres A, et al. Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppressive regimen. Transpl Int. 2005;18(11):1226–30.

    Article  CAS  Google Scholar 

  30. Fung MA, et al. The effect of medical therapy and islet cell transplantation on diabetic nephropathy: an interim report. Transplantation. 2007;84(1):17–22.

    Article  Google Scholar 

  31. Kawahara T, et al. Portal vein thrombosis is a potentially preventable complication in clinical islet transplantation. Am J Transplant. 2011;11(12):2700–7.

    Article  CAS  Google Scholar 

  32. Collaborative islet transplant registry, Ninth annual report. 2016. http://www.citregistry.org/.

  33. Dominguez-Bendala J, et al. The human endocrine pancreas: new insights on replacement and regeneration. Trends Endocrinol Metab. 2016;27(3):153–62.

    Article  CAS  Google Scholar 

  34. Calafiore R, et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care. 2006;29(1):137–8.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diabetology, CHU Grenoble Alpes, Grenoble, France

    Sandrine Lablanche & Pierre-Yves Benhamou

  2. Laboratory of Fundamental and Applied Bioenergetics, Grenoble Alpes University, Grenoble, France

    Sandrine Lablanche, Camille Laporte & Pierre-Yves Benhamou

Authors
  1. Sandrine Lablanche
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Camille Laporte
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre-Yves Benhamou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sandrine Lablanche .

Editor information

Editors and Affiliations

  1. Department of Endocrinology, Centre Hospitalier Universitaire de Caen, CAEN CEDEX 9, France

    Yves Reznik

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lablanche, S., Laporte, C., Benhamou, PY. (2019). Islet Transplantation. In: Reznik, Y. (eds) Handbook of Diabetes Technology. Springer, Cham. https://doi.org/10.1007/978-3-319-98119-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98119-2_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98118-5

  • Online ISBN: 978-3-319-98119-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation